This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Burtness B , Marur S , Bauman JE , Golemis EA , Mehra R , Cohen SJ
Comment on "epidermal growth factor receptor is essential for toll-like receptor 3 signaling"
Sci Signal. 2012 ;5(254) :lc5
AbstractEpidermal growth factor receptor (EGFR) and mammalian target of rapamycin (mTOR) play important roles in tumor growth, which has stimulated efforts toward the design of targeted cancer therapeutics that inhibit their function. A growing body of literature indicates that EGFR and mTOR are also essential to support a functional innate immune response. Hence, although combination therapies that block both EGFR and mTOR may have improved activity against tumors, they may also place patients at risk of fulminant infections. We discuss data supporting this hypothesis.
NotesBurtness, Barbara Marur, Shanthi Bauman, Julie E Golemis, Erica A Mehra, Ranee Cohen, Steven J United States Science signaling Sci Signal. 2012 Dec 11;5(254):lc5. doi: 10.1126/scisignal.2003734.